Guías Clínicas
Guías tam izaje, d iagn óstico y tratam ien to de l hepa toca rcinoma - Sociedad Chilena de Gastroenterología
Comparison of 7 Staging Systems
in an American Cohort. Hepatology.
2005;41:707-16.
104.- Cillo U, Vitale A, Grigoletto F, Farinati
F, Brolese A, Zanus G, et al. Prospective
Validation of the Barcelona Clinic Liver
Cancer Staging System. J Hepatol.
2006;44:723-31.
105.- European Association for The Study
Of The Liver; European Organisation
For Research And Treatment Of
Cancer. EASL-EORTC Clinical
Practice Guidelines: Management of
Hepatocellular Carcinoma. J Hepatol.
2012;56:908-43.
106.- Méndez-Sánchez N, Ridruejo E, de
Mattos AA, Chávez-Tapia NC, Zapata
R, Paraná R, et al. Latin American
Association for the Study of the Liver
(LAASL) Clinical Practice Guidelines:
Management of Hepatocellular
Carcinoma. Vol. 13, Ann Hepatol. 2014.
S4-40 p.
107.- Kim BK, Kim SU, Park JY, Kim DY,
Ahn SH, Park MS, et al. Applicability of
BCLC Stage for Prognostic Stratification
in Comparison with other Staging
Systems: Single Centre Experience
from Long-Term Clinical Outcomes of
1717 Treatment-Naïve Patients with
Hepatocellular Carcinoma. Liver Int.
2012;32:1120-7.
108.- Gomaa AI, Hashim MS, Waked I.
Comparing Staging Systems for
Predicting Prognosis and Survival in
Patients with Hepatocellular Carcinoma
in Egypt. PLoS One. 2014;9:e90929.
109.- Forner A, Reig M, Varela M, Burrel M,
Feliu J, Briceño J, et al. Diagnosis and
Treatment of Hepatocelular Carcinoma.
Update Consensus Document from the
AEEH, SEOM, SERAM, SERVEI and
SETH. Med Clin. 2016;146:511.e1-511.
e22.
110.- Wallace MC, Huang Y, Preen DB, Garas
G, Adams LA, MacQuillan G, et al.
HKLC Triages More Hepatocellular
Carcinoma Patients to Curative
Therapies Compared to BCLC and Is
Associated with Better Survival. Dig Dis
Sci. 2017;62:2182-92.
111.- Liu PH, Hsu CY, Lee YH, Su CW,
Hsia CY, Huang YH, et al. Hong
Kong Liver Cancer Staging System is
Associated with Better Performance
for Hepatocellular Carcinoma: Special
100
Emphasis on Viral Etiology. Med.
2015;94:e1772.
112.- Sohn JH, Duran R, Zhao Y, Fleckenstein
F, Chapiro J, Sahu S, et al. Validation of
the Hong Kong Liver Cancer Staging
System in Determining Prognosis of
the North American Patients Following
Intra-arterial Therapy. Clin Gastroenterol
Hepatol. 2017;15:746-55.
113.- Liu S, Li X, Li H, Guo L, Zhang
B, Zhang J, et al. Is the Hong Kong
Liver Cancer Staging System the Best
Guide for Hepatitis B Virus-related
Hepatocellular Carcinoma Patients
with Multiple Tumors? Oncotarget.
2016;7:51598-607.
114.- Parikh ND, Scaglione S, Li Y, Powell
C, Yerokun OA, Devlin P, et al. A
Comparison of Staging Systems
for Hepatocellular Carcinoma in
a Multicenter US Cohort. Clin
Gastroenterol Hepatol. 2018;16:781-2.
115.- Selby L, Tay R, Woon W, Low J,
Bei W, Shelat V, et al. Validity of the
Barcelona Clinic Liver Cancer and
Hong Kong Liver Cancer Staging
Systems for Hepatocellular Carcinoma in
Singapore. J Hepatobiliary Pancreat Sci.
2017;24:143-52.
116.- Lee Y-S, Seo YS, Kim JH, Lee J, Kim
HR, Yoo YJ, et al. Can More Aggressive
Treatment Improve Prognosis in Patients
with Hepatocellular Carcinoma? A
Direct Comparison of the Hong Kong
Liver Cancer and Barcelona Clinic
Liver Cancer Algorithms. Gut Liver.
2018;12:94-101.
117.- Kim KM, Sinn DH, Jung SH, Gwak
GY, Paik YH, Choi MS, et al. The
Recommended Treatment Algorithms of
the BCLC and HKLC Staging Systems:
Does Following These Always Improve
Survival Rates for CHC Patients? Liver
Int. 2016;36:1490-7.
118.- Adhoute X, Penaranda G, Bronowicki
J-P, Raoul J-L. Usefulness of the
HKLC vs. the BCLC Staging System
in a European CHC Cohort. J Hepatol.
2015;62:492-3.
119.- Chen S Sen, Yu KK, Ling QX, Huang C,
Li N, Zheng JM, et al. The Combination
of Three Molecular Markers Can Be
a Valuable Predictive Tool for the
Prognosis of Hepatocellular Carcinoma
Patients. Sci Rep. 2016;6:1-9.
120.- Zhou N, Wu J, Wang X, Sun Z, Han
Q, Zhao L. Low-level Expression of
MicroRNA-375 Predicts Poor Prognosis
in Hepatocellular Carcinoma. Tumor
Biol. 2015;37:2145-52.
121.- Mazafferro V, Regali E, Doci R,
Andreola S, Pulvirenti A, Bozzetti
F, et al. Liver Transplantation for the
Treatment of Small Hepatocellular
Carcinomas in Patients with Cirrhosis. N
Engl J Med. 1996;334:693-9.
122.- Mazzaferro V, Bhoori S, Sposito C,
Bongini M, Langer M, Miceli R, et al.
Milan Criteria in Liver Transplantation
for Hepatocellular Carcinoma : An
Evidence-Based Analysis of 15 Years
of Experience. Liver Transplant.
2011;17:S44-57.
123.- Yao FRYY, Errell LIF, Bass NA, Watson
JEJ, Bacchetti PE, Venook ALAN, et al.
Liver Transplantation for Hepatocellular
Carcinoma : Expansion of the Tumor
Size Limits Does Not Adversely Impact
Survival. Hepatology. 2001;33:1394-
405.
124.- Duffy JP, Vardanian A, Benjamin E,
Watson M. Liver Transplantation Criteria
For Hepatocellular Carcinoma Should
Be Expanded: A 22-Year Experience
With 467 Patients at UCLA. Ann Surg.
2007;246:502-11.
125.- Yao F, Xiao L, Bass N, Kerlan R, NL
A, Roberts J. Liver Transplantation for
Hepatocellular Carcinoma : Validation of
the UCSF-Expanded Criteria Based on
Preoperative Imaging. Am Jour Transp.
2007;7:2587-96.
126.- Maggs JRL, Suddle AR, Aluvihare V,
Heneghan MA. Systematic Review :
the Role of Liver Transplantation in
the Management of Hepatocellular
Carcinoma. Aliment Pharmacol Ther.
2012;35:1113-34.
127.- Costentin C, Amaddeo G, Decaens T,
Boudjema K, Bachellier P, Muscari
F, et al. Prediction of Hepatocellular
Carcinoma Recurrence After Liver
Transplantation: Comparison of 4
Explant-based Prognostic Models. Liver
Int. 2017;37:717-26.
128.- Hanouneh IA, Macaron C, López R,
Aucejo F, Zein NN. Rate of Tumor
Growth Predicts Recurrence of
Hepatocellular Carcinoma After Liver
Transplantation in Patients Beyond
Milan or UCSF Criteria. Transplant
Proc. 2011;43:3813-8.
Gastroenterol. latinoam 2019; Vol 30, Nº 2: 64-106